HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Guidelines, predictive models needed to improve understanding of second primary malignancies
-
- Answer to debate over mammography likely found ‘somewhere in the middle’ Rachel C. Jankowitz, MD; Adam M. Brufsky, MD, PhD
- Several agents in development may help overcome resistance in advanced prostate cancer Daniel P. Petrylak, MD
- Alternate sunitinib schedule decreased toxicity in mRCC
- Cetuximab plus chemotherapy effective in NSCLC
- Serum VEGF levels predicted response to ipilimumab in advanced melanoma
- Early metastatic volume decrease after stereotactic radiosurgery linked to prolonged local control
- NLR predicted outcomes in patients with lung cancer, VTE
- Vemurafenib decreased lymphocyte counts, altered T-cells in melanoma
-
- Active TB increased VTE risk
- ADT may cause short-term changes in emotional quality of life
- Eltrombopag restored hematopoiesis in refractory severe aplastic anemia
- Lower vancomycin dosage inadequate in younger oncology patients
- Mammography did not reduce breast cancer mortality
- R-CHOP plus radiation improved outcomes in bulky B-cell lymphoma
- Second-line docetaxel effective in refractory esophagogastric adenocarcinoma
- Maintenance regimen improved survival in transplant-ineligible patients with myeloma
-
- Gefitinib, erlotinib increased risk for interstitial lung disease in patients with advanced NSCLC
- PFS may be surrogate for OS in glioblastoma
- AACR announces president-elect
- Children’s hospital appoints BMT director
- Hem/onc appointed NCI board vice chair
- Medical center appoints chief of hematology/oncology
- Penn State appoints cancer institute director
- Pharmacy group presents award
-
- High facility volume improved gynecologic cancer survival
- BRCA1 mutation increased risk for rare uterine cancers after salpingo-oophorectomy
- Risk for OPSCC death halved among patients with HPV positive tumors
- Unilateral radiation benefited patients with advanced tonsil cancer